Bristol-Myers Squibb to acquire Celgene in $74bn deal
03-01-2019
360b / Shutterstock.com
Pharmaceutical company Bristol-Myers Squibb (BMS) has acquired Cormorant Pharmaceuticals in a deal valued at up to $95 million.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Bristol-Myers Squibb, Cormorant, IL-8
